

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

MOLINARI et al.

Art Unit: 1641

Application No.: Cont. of 08/603,182

Examiner: J. Grun

Filed: January 30, 2004

Attorney Dkt. No.: 101615-00029

For: ANTI-HIRUDIN POLYCLONAL ANTIBODIES AND THEIR USE FOR
IDENTIFICATION, IMMUNOPURIFICATION AND QUANTITATIVE
DETERMINATION OF HIRUDIN

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. PTO
P.O. Box 1450
Alexandria, VA 22313-1450

January 30, 2004

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information

Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☒ 4. The references were cited by or submitted to the Office in parent application No. 08/603,182, filed February 20, 1996, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these references are not attached. 37 CFR § 1.98(d).

Respectfully submitted,



Amy E.L. Schoenhard
Registration No. 46,512

Customer No. 004372
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

ALS:ksm

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 101615-00029	SERIAL NO. Cont. of 08/603,182
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT MOLINARI et al.	
		FILING DATE January 30, 2004	GROUP 1641 (expected)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	5,272,059	12/21/1993	SCHLAEPPi et al.	435	70.21	1/18/1990
	AB	5,114,922	5/19/1992	MASCHLER et al.	514	12	6/8/1989
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AG	0 380 443	08/01/1990	EUROPE					
	AH	0 074 248	03/16/1983	EUROPE					
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Schlaeppli, "Preparation of Monoclonal Antibodies to the Thrombin/Hirudin Complex", Thrombosis Res., 62, p. 459-70 (June 1991).
	AN	Man et al., "Treatment of Human Myocardial Infarction with Glutaraldehyde Preferentially Increases the Immunology", J. Immunological Meth. 125, p. 251-9 (1989).
	AO	Reichlin et al., "Immunological Activity of Cytochrome C", J. Biological Chem., 245, p. 945-954 (1970).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 101615-00029	SERIAL NO. Cont. of 08/603,182
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT MOLINARI et al.	
		FILING DATE January 30, 2004	GROUP 1641 (expected)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	BM	De Taxis du Poet et al., "Production of HVI Variant of Hirudin by Recombinant DNA Methodology", Blood Coag. And Fibro. 2, p. 113-120 (1991).
	BN	Dotd et al., "Expression, Secretion and Procession of Hirudin in E. Coli Using the Alkaline Phosphatase Signal Sequence, Febs. Lett. 202, p. 373-377 (1986).
	BO	Fort Kamp et al., "Cloning and Expression in Escherichia Coli of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor of the Leech", DNA, 5, p. 511-517 (1986)
	BP	Harvey et al., "Cloning and Expression of a cDNA Coding for the Anticoagulant Hirudin from the Bloodsucking Leech", PNAS, 83, 1084-1088 (1986).
	BQ	Schlaeppli et al., "Preparation of Monoclonal Antibodies to Hirudin and Hirudin Peptides", Eur. J. Biochem., 188, 2, p. 463-470 (1990).
	BR	Spinner et al., "Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) for Hirudin", J. Immunol. Meth., 87, p. 79-83 (1986).
	BS	Maurer et al., "Proteins and Polypeptides as Antigens", Meth. In Enzymol., 70, p. 49-70 (1980).
	BT	Chemical Abstracts, Vol. 98, No. 3, p. 390 (1/17/1983).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	